BRAF and neoplasm: CDx biomarkers (including BRAF, EGFR, PIK3CA, and RAS mutations) and other tumor profiling biomarkers (including clinically relevant alterations and TMB) were represented in marker positive samples diluted with lineage matched marker negative samples.